IBJNews

Chao exit hurts drug development industry

Back to TopCommentsE-mailPrintBookmark and Share

Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.

The Chao Center formulated and manufactured small batches of chemical drugs used in clinical trials and performed analysis on experimental drugs. Purdue is hoping to find a private company to come in and take over the 5-year-old facility.

“That is a loss for our system,” said BioCrossroads CEO David Johnson. “It’s more a loss for the scientific part of our system than the business part.”

What BioCrossroads hoped to do was to package and pitch a full range of services offered by Indiana companies to help small drug-discovery firms move their experimental compounds through the various stages of testing. BioCrossroads still maintains an office in one of the nation's hotspots for drug discovery, San Diego.

But since that office opened in early 2008, the entire industry has changed. When the stock market melted down in late 2008, venture capital dried up for drug- discovery firms, pushing them to seek out large pharmaceutical companies to help develop their drugs.

As such deals were struck, large drug companies, such as Indianapolis-based Eli Lilly and Co., were also looking to outsource more work to contract research and manufacturing firms as a way to reduce their costs.

“The contract drug development is brisker than ever, but you’ve got to pay attention to who’s paying the bills,” Johnson said. More often, big pharma is writing the checks, he said, even if a drug being developed is owned by a small biotech firm.

The recession prevented the Chao Center for Industrial Pharmacy and Contract Manufacturing from getting enough business to make a profit, according to Joe Hornett, director of the Purdue Research Park. The Chao Center’s most consistent work was making seromycin, a medicine to treat drug-resistant tuberculosis, for Lilly.

It’s not clear how much interest the Chao Center might generate among private contract-manufacturing firms. Lilly successfully sold its manufacturing facility in Lafayette to Germany-based Evonik AG last year, after shopping it for a year, by promising to be the facility’s first customer.

Johnson said Purdue could also package itself and its scientists as it pitches the Chao Center to private firms. “The attraction for an outside party would obviously be the relationship with Purdue,” he said.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. How can any company that has the cash and other assets be allowed to simply foreclose and not pay the debt? Simon, pay the debt and sell the property yourself. Don't just stiff the bank with the loan and require them to find a buyer.

  2. If you only knew....

  3. The proposal is structured in such a way that a private company (who has competitors in the marketplace) has struck a deal to get "financing" through utility ratepayers via IPL. Competitors to BlueIndy are at disadvantage now. The story isn't "how green can we be" but how creative "financing" through captive ratepayers benefits a company whose proposal should sink or float in the competitive marketplace without customer funding. If it was a great idea there would be financing available. IBJ needs to be doing a story on the utility ratemaking piece of this (which is pretty complicated) but instead it suggests that folks are whining about paying for being green.

  4. The facts contained in your post make your position so much more credible than those based on sheer emotion. Thanks for enlightening us.

  5. Please consider a couple of economic realities: First, retail is more consolidated now than it was when malls like this were built. There used to be many department stores. Now, in essence, there is one--Macy's. Right off, you've eliminated the need for multiple anchor stores in malls. And in-line retailers have consolidated or folded or have stopped building new stores because so much of their business is now online. The Limited, for example, Next, malls are closing all over the country, even some of the former gems are now derelict.Times change. And finally, as the income level of any particular area declines, so do the retail offerings. Sad, but true.

ADVERTISEMENT